Sanofi Pasteur Biologics, LLC

Sanofi Pasteur Biologics Co.

Florida State University Research Foundation, Inc.

Acambis Inc.

Konstantin V Pugachev

Thomas P Monath

Farshad Guirakhoo

Juan Arroyo

Harold Kleanthous

John Avram Catalan

J Jian Liu

Maryann Giel-Moloney

Jian Liu

Mark Parrington

Linong Zhang

Alexander A Rumyantsev

Teryl K Frey

Emily S Abernathy

Wen-Pin Tzeng

John A Catalan

The invention provides flavivirus vaccines and methods of making and using these vaccines.

Flavivirus vaccines

This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.

Replication-defective flavivirus vaccines and vaccine vectors

The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.

[object Object]

The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.

Vaccines against japanese encephalitis virus and west nile virus

Recombinant flavivirus vaccines

The invention provides attenuatedvaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.

Vaccines against Japanese encephalitis virus and West Nile virus

Chimeric flaviviruses

Highly infectious rubella virus cDNA clones derived from infectious cDNA clone having a low specific infectivity and methods of obtaining highly infectious rubella virus cDNA clones. Togavirus expression vectors of improved stability for the expression of live, attenuated togavirus and a foreign gene, based on the nucleic acid sequence of an infectious rubella virus clone and contain a togavirus non-structural protein open reading frame; an expression element for expression of a foreign gene; a foreign gene or a multiple cloning site for insertion of a foreign gene; an expression element for the expression of the live, attenuated togavirus; and a togavirus structural protein open reading frame. The expression element is either a subgenomic promoter or an internal ribosome entry site (IRES). Administration of the vector as an immunization agents is useful for the induction of immuity against the togavirus, the foreign gene, or both.

Highly infectious rubella virus DNA constructs and methods of production

Growing community of inventors

Natick, MA, United States of America

Konstantin V Pugachev